• Azer-cel Phase 1b trial achieves 82% overall response rate in relapsed/refractory DLBCL
• CAR T naïve cohort expansion shows strong results with 83% overall response rate
• FDA meeting validates azer-cel strategy, providing pathway to pivotal trial
• New collaboration with JW Therapeutics to advance onCARlytics program

Imugene Limited, a clinical-stage immuno-oncology company, has reported its Quarterly Cash Flow report for the quarter ended 31 December 2025. The key highlights include:Azer-cel Phase 1b Trial Achieves 82% Overall Response Rate: The company reported an 82% overall response rate in its ongoing Phase 1b clinical trial of azer-cel, an allogeneic, off-the-shelf CD19 CAR T cell therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Of the 17 evaluable patients, 14 responded to therapy, including seven Complete Responses and seven Partial Responses.CAR T Naïve Cohort Expansion Shows Strong Results: Imugene expanded the trial to include CAR T naïve patients, targeting a broad spectrum of Non-Hodgkin lymphomas. Early data from this cohort showed an 83% overall response rate, including a 50% complete response rate.FDA Meeting Validates Azer-cel Strategy: The company's meeting with the FDA was overwhelmingly positive, validating critical components of the azer-cel strategy, including dosing regimen, patient population, endpoints, and manufacturing readiness. This provides a clear pathway to advance azer-cel into a pivotal study.New Collaboration with JW Therapeutics: Imugene entered a strategic collaboration with JW Therapeutics to evaluate a combination therapy using Imugene's onCARlytics oncolytic virus and JW's Carteyva® CD19 CAR T cell therapy in solid tumors.Financial Updates: Imugene amended its convertible notes to improve cash flow management, and expects operating costs for the 12 months ending 30 June 2026 to be approximately 50% lower than the prior financial year.

Imugene expects its operating costs for the 12 months ending 30 June 2026 to be substantially lower than those of the prior financial year, with headcount significantly reduced following the sale of the manufacturing facility.